# US 2021/0139429 A1 · Compounds for treatment of cardiac arrhythmias and heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0139429 A1
- Document ID: US20210139429A1
- Status: Published application
- Kind: A1
- Application number: 17/042,616
- Filed: 2019-03-28
- Published: 2021-05-13
- Earliest claimed: 2018-03-29
- Assignees: Elex Biotech, Inc.
- Applicants: Elex Biotech, Inc.
- Inventors: Josephrajan THAINASHMUTHU; Martha SIBRIAN-VAZQUEZ; Douglas BOATMAN
- Web page: https://patentgrep.com/patent/US20210139429A1

## CPC

- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- C07C 211/49: having at least two amino groups bound to the carbon skeleton
- C07C 217/88: the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 229/64: the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C 309/24: of a carbon skeleton containing six-membered aromatic rings
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 215/20: Oxygen atoms
- C07D 215/36: Sulfur atoms (C07D215/24 takes precedence)
- C07D 217/04: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 217/24: Oxygen atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 249/06: with aryl radicals directly attached to ring atoms
- C07D 249/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 257/04: Five-membered rings
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 295/13: to an acyclic saturated chain
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanodine receptors. Some of the compounds have a structure according to formula I, or a stereoisomer, tautomer, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound according to formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof
wherein:
RA is —N(R1)R2 and RB is H, aliphatic, —O-aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen, or RA is N(R1) or —CH2N(R1)— and RA together with RB forms a 5- or 6-membered heteroaliphatic or heteroaryl ring;
RC is H, aliphatic, —S-aliphatic, or —O—C(O)-aliphatic, and RD is substituted aliphatic or —Y—X—(CR72)m—N(R4)R5, or RC and RD together form a 5- or 6-membered heteroaliphatic or heteroaryl ring, wherein the 5- or 6-membered heteroaliphatic or heteroaryl ring is substituted with —X—(CR72)m—N(R4)R5;
RE is H, —O-aliphatic, aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen;
Q is C—R3;
X is N(R6), O, C(O), —S(O2)O—, —OS(O2)—, —P(O)(OH)O—, —OP(O)OH—, —N(H)—C(H)(CF3)—, or —C(H)(CF3)—N(H)—, or X is absent;
Y is —(CR72)n— or a divalent azole ring;
R1 and R2 independently are H or aliphatic;
R3 is H, aliphatic, —O-aliphatic, or —S-aliphatic;
R4 and R5 independently are H, aliphatic, aryl or heteroaryl, or R4 and R5 together with N form a heterocycloaliphatic or heteroaryl ring;
R6 is H or aliphatic;
each R7 independently is H, halogen, or aliphatic; and
m and n independently are integers from 1 to 10,
wherein at least one of the following conditions applies
(i) at least one of RB, RC, RE, and R3 is other than H, or
(ii) the compound includes —Y—X—(CR72)m—N(R4)R5 or —X—(CR72)m—N(R4)R5, where X is present, or
(iii) if Y is a divalent azole ring, then X is absent, or
(iv) if R4 and R5 together with N form a heterocycloaliphatic or heteroaryl ring, then at least of one of RB, RC, RE, and R3 is other than H, or at least one of R1 and R2 is other than H or —CH3; or
(v) if X is absent, then the compound has a structure according to formula III
where Y is a divalent azole ring; or
(vi) if RC and RD together form a 5- or 6-membered heteroaliphatic or heteroaryl ring, then the compound has a structure according to formula IV or formula VI
where (a) Z is O, N(H), or CH2, and (b) r is 1 or 2, s is 1 or 2, and r+s=2 or 3, and wherein the compound is not

### Claim 2 (depends on 1)

The compound according to claim 1, wherein RD is —Y—X—(CR72)m—N(R4)R5.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound has a structure according to one of formulas II, III, IV, V, VI, or VII
wherein:
RA is N(R1) or —CH2N(R1)—;
RB is H, aliphatic, —O-aliphatic, —S-aliphatic, or halogen;
RC is H or aliphatic;
RD is —(CH2)qSO3M, —(CH2)qNH2, or —(CH2)qOH, where q is an integer from 1 to 10 and M is a monatomic cation;
X is N(R6), O, C(O), —S(O2)O—, —OS(O2)—, —P(O)(OH)O—, —OP(O)(OH)3, —N(H)—C(H)(CF3)— or —C(H)(CF3)—N(H)—;
Y is a divalent azole ring;
Z is O, N(H), or CH2;
p is 1, 2, or 3 when RA is N(R1), or p is 1 or 2 when RA is —CH2N(R1)—;
q is an integer from 1 to 10; and
r is 1 or 2, s is 1 or 2, and r+s=2 or 3,
wherein if the compound has a structure according to formula II, then at least one of the following conditions applies
(i) at least one of R1 and R2 is other than H, or
(ii) at least one of RC and RE is other than H, or
(iii) X is other than N(H), or
(iv) m is not 2, or
(v) n is not 1, or
(vi) if Q is CH then RB is not —O-aliphatic, or
(vii) if RB is H then Q is not C—R3 where R3 is —O-aliphatic.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein the compound has a structure according to Formula II, and X is N(R6) where R6 is aliphatic.

### Claim 5 (depends on 3)

The compound according to claim 3, wherein the compound has a structure according to formula III, and Y is an imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, furazanyl, thiazolyl, isothiazolyl, or thiadiazolyl group.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The compound according to claim 5, wherein Y is a tetrazolyl or oxadiazolyl group.

### Claim 8 (depends on 3)

The compound according to claim 3, wherein the compound has a structure according to one of formulas IIIA, IIIB, IIIC, IIID, VA, VB, VC, VIA, VIB, or VIC
wherein:
if the compound has a structure according to formula IIIA, then at least one of R1 and R2 is other than H, or at least one of RB, RC, and RE is other than H, or Q is other than CH, or
if the compound has a structure according formula VIA, then at least one of RB, RE, or R3 is other than H, or m is not 2, or if one of R1 and R2 is H, then the other of R1 and R2 is other than H or CH3, or
if the compound has a structure according to formula VIB, then at least one of RB, RE, or R3 is other than H, or m is not 2, or at least one of R1 and R2 is other than H, or at least one of R4 and R5 is other than —CH3.

### Claim at position 9

9-11. (canceled)

### Claim 12 (depends on 1)

The compound according to claim 1, wherein:
(i) R4 and R5 are alkyl; or
(ii) m is 2, or n is 1, or m is 2 and n is 1; or
(iii) R6 is H, or each R7 is H, or R6 is H and each R7 is H; or
(iv) any combination thereof.

### Claim at position 11

13-18. (canceled)

### Claim 19 (depends on 1)

The compound according to claim 1, wherein:
RA is —N(R1)R2 where R1 is H or aliphatic and R2 is H or aliphatic;
RB is H, aliphatic, —O-aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen;
RC is H, aliphatic, —S-aliphatic, or —O—C(O)-aliphatic; and
RD is —(CH2)qNH2, —(CH2)qOH, or —(CH2)qSO3M where q is an integer from 1 to 10 and M is a monatomic cation.

### Claim at position 13

20-22. (canceled)

### Claim 23 (depends on 1)

The compound according to claim 1, wherein the compound is:
N1-(4-amino-2-methoxybenzyl)-N2,N2-diethylethane-1,2-diamine;
3-methoxy-4-(((2-(pyrrolidin-1-yl)ethyl)amino)methyl)aniline;
sodium (4-amino-2-methoxyphenyl)methanesulfonate;
N-butyl-2-(2-(diethylamino)ethyl)isoindolin-5-amine;
N-butyl-2-(2-(pyrrolidin-1-yl)ethyl)isoindolin-5-amine;
sodium (4-(dibutylamino)-3-methoxyphenyl)methanesulfonate;
sodium (4-amino-3-methoxyphenyl)methanesulfonate;
4-((2-(diethylamino)ethoxy)methyl)-2,3-dimethoxyaniline;
N-butyl-4-(3-((diethylamino)methyl)-1,2,4-oxadiazol-5-yl)-3-methoxyaniline;
N-butyl-4-(3-((dimethylamino)methyl)-1,2,4-oxadiazol-5-yl)-3-methoxyaniline;
N-butyl-4-(3-((dibutylamino)methyl)-1,2,4-oxadiazol-5-yl)-3-methoxyaniline;
N-butyl-4-(3-((dibutylamino)methyl)-1,2,4-oxadiazol-5-yl)-2-methylaniline;
N1-((1-butyl-1,2,3,4-tetrahydroquinolin-6-yl)methyl)-N2,N2-dimethylethane-1,2-diamine;
N-butyl-4-(1-(2-(dibutylamino)ethyl)-1H-tetrazol-5-yl)-2-methylaniline;
2-(2-(diethylamino)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-amine;
N3-(2-(diethylamino)ethyl)-1H-indazole-3,6-diamine;
N6,N6-dibutyl-N3-(2-(diethylamino)ethyl)-1H-indazole-3,6-diamine;
N1-((1-butyl-1,2,3,4-tetrahydroquinolin-6-yl)methyl)-N2,N2-diethylethane-1,2-diamine;
N1-(4-amino-3-methylbenzyl)-N2,N2-diethylethane-1,2-diamine;
N-butyl-2-(2-(diethylamino)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-amine; or
N-butyl-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-amine.

### Claim 24 (depends on 1)

A pharmaceutical composition, comprising:
a therapeutically effective amount of at least one compound according to claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof; and
at least one pharmaceutically acceptable additive.

### Claim 25 (depends on 1)

A method, comprising:
modulating activity of a calcium ion channel by contacting the calcium ion channel with an effective amount of a compound according to claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein contacting the calcium ion channel with the compound inhibits activity of the calcium ion channel.

### Claim 27 (depends on 25)

The method of claim 25, wherein the calcium ion channel is a ryanodine receptor.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The method of claim 25, wherein contacting the calcium ion channel comprises administering the effective amount of the compound, or stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof, to a subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject is a subject identified as having, or being at risk of having, a cardiac arrhythmia or heart failure.

### Claim 31

(canceled)

### Claim 32 (depends on 25)

The method of claim 25, wherein the compound is:
N1-(4-amino-2-methoxybenzyl)-N2,N2-diethylethane-1,2-diamine;
3-methoxy-4-(((2-(pyrrolidin-1-yl)ethyl)amino)methyl)aniline;
sodium (4-amino-2-methoxyphenyl)methanesulfonate;
N-butyl-2-(2-(diethylamino)ethyl)isoindolin-5-amine;
N-butyl-2-(2-(pyrrolidin-1-yl)ethyl)isoindolin-5-amine; or
any combination thereof.

### Claim 33 (depends on 1)

A method for ameliorating at least one sign or symptom of a cardiac arrhythmia or heart failure, the method comprising:
administering one or more therapeutically effective doses of a compound according to claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof, over an effective period of time to a subject identified as having, or being at risk of having, a cardiac arrhythmia or heart failure, thereby ameliorating at least one sign or symptom of the cardiac arrhythmia or heart failure.

### Claim at position 25

34-36. (canceled)

### Claim 37 (depends on 33)

The method of claim 33, wherein the compound is:
N1-(4-amino-2-methoxybenzyl)-N2,N2-diethylethane-1,2-diamine;
3-methoxy-4-(((2-(pyrrolidin-1-yl)ethyl)amino)methyl)aniline;
sodium (4-amino-2-methoxyphenyl)methanesulfonate;
N-butyl-2-(2-(diethylamino)ethyl)isoindolin-5-amine;
N-butyl-2-(2-(pyrrolidin-1-yl)ethyl)isoindolin-5-amine; or
any combination thereof.

### Claim 38 (depends on 25)

The method of claim 25, wherein the compound has a calcium spark response IC50 value within a range of from 20 nM to 500 nM as determined in cells from a catecholaminergic polymorphic ventricular tachycardic (CPVT) mouse model.
